These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 11030738

  • 1. The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice.
    Matsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, Uematsu T.
    Br J Pharmacol; 2000 Oct; 131(4):858-64. PubMed ID: 11030738
    [Abstract] [Full Text] [Related]

  • 2. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
    Matsuno H, Kozawa O, Niwa M, Ueshima S, Matsuo O, Collen D, Uematsu T.
    Thromb Haemost; 1999 Apr; 81(4):601-4. PubMed ID: 10235447
    [Abstract] [Full Text] [Related]

  • 3. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
    Azzam K, Cissé-Thiam M, Drouet L.
    Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
    [Abstract] [Full Text] [Related]

  • 4. tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor.
    Nishida M, Matsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, Uematsu T.
    J Cardiovasc Pharmacol; 2000 Dec; 36(6):770-5. PubMed ID: 11117378
    [Abstract] [Full Text] [Related]

  • 5. Lack of tPA significantly affects antithrombotic therapy by a GPIIb/IIIa antagonist, but not by a thrombin inhibitor in mice.
    Matsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, Uematsu T.
    Thromb Haemost; 2000 Apr; 83(4):605-9. PubMed ID: 10780325
    [Abstract] [Full Text] [Related]

  • 6. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery.
    Kaida T, Matsuno H, Niwa M, Kozawa O, Miyata H, Uematsu T.
    Thromb Haemost; 1997 Mar; 77(3):562-7. PubMed ID: 9066011
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tissue type plasminogen activator facilitates NMDA-receptor-mediated retinal apoptosis through an independent fibrinolytic cascade.
    Kumada M, Niwa M, Hara A, Matsuno H, Mori H, Ueshima S, Matsuo O, Yamamoto T, Kozawa O.
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1504-7. PubMed ID: 15790922
    [Abstract] [Full Text] [Related]

  • 9. Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice.
    Matsuno H, Kozawa O, Okada K, Ueshima S, Matsuo O, Uematsu T.
    Thromb Haemost; 2002 Jan; 87(1):98-104. PubMed ID: 11848464
    [Abstract] [Full Text] [Related]

  • 10. The role of the plasminogen system in bone resorption in vitro.
    Daci E, Udagawa N, Martin TJ, Bouillon R, Carmeliet G.
    J Bone Miner Res; 1999 Jun; 14(6):946-52. PubMed ID: 10352103
    [Abstract] [Full Text] [Related]

  • 11. The role of the fibrinolytic system in corneal angiogenesis.
    Vogten JM, Reijerkerk A, Meijers JC, Voest EE, Borel Rinkes IH, Gebbink MF.
    Angiogenesis; 2003 Jun; 6(4):311-6. PubMed ID: 15166500
    [Abstract] [Full Text] [Related]

  • 12. Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery.
    Matsuno H, Kozawa O, Niwa M, Tanabe K, Ichimaru K, Takiguchi Y, Yokota M, Hayashi H, Uematsu T.
    Thromb Haemost; 1998 Apr; 79(4):865-71. PubMed ID: 9569206
    [Abstract] [Full Text] [Related]

  • 13. Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles.
    Rupin A, Martin F, Vallez MO, Bonhomme E, Verbeuren TJ.
    Thromb Haemost; 2001 Dec; 86(6):1528-31. PubMed ID: 11776323
    [Abstract] [Full Text] [Related]

  • 14. Antithrombotic properties of water-soluble carbon monoxide-releasing molecules.
    Kramkowski K, Leszczynska A, Mogielnicki A, Chlopicki S, Fedorowicz A, Grochal E, Mann B, Brzoska T, Urano T, Motterlini R, Buczko W.
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2149-57. PubMed ID: 22772756
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brünner N, Sweep CG, Duffy MJ.
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [Abstract] [Full Text] [Related]

  • 17. Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).
    Shen GX.
    Int J Mol Med; 1998 Feb; 1(2):399-408. PubMed ID: 9852242
    [Abstract] [Full Text] [Related]

  • 18. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
    Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ.
    Cancer Res; 2000 Oct 15; 60(20):5839-47. PubMed ID: 11059781
    [Abstract] [Full Text] [Related]

  • 19. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A, Brun P, Sartori MT, Cortivo R, Dedominicis C, Saggiorato G, Abatangelo G, Secchi AG.
    Invest Ophthalmol Vis Sci; 2005 Apr 15; 46(4):1364-70. PubMed ID: 15790903
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.